SCHEMBL23320127

SCHEMBL23320127

O=C(c1ccc(Cl)cc1)c1ccsc1NC=S

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 1/20 0.41
MAPK8 P45983 1/20 0.41
NR4A1 P22736 1/20 0.41
SRD5A2 P31213 1/20 0.39
MAPK1 P28482 1/20 0.39
GAA P10253 2/20 0.38
NPC1 O15118 2/20 0.38
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
PRNP P04156 1/20 0.37
USP2 O75604 1/20 0.36
GLA P06280 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319960 0.76 ALDH1A1 (0.63) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21914746 0.74 MAPT (0.41) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23320326 0.71 ALDH1A1 (0.56) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5505167 0.71 MEN1 (1.00) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23320095 0.69 RAB9A (0.48) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7475833 0.68 RAB9A (0.59) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21847322 0.68 RAB9A (0.55) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21847193 0.68 MEN1 (0.46) RAB9AMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL9065412 0.64 SRD5A2 (0.80) ALDH1A1LMNAMAPTHTTNR4A1
SCHEMBL51827 0.64 SRD5A2 (0.80) ALDH1A1LMNAMAPTHTTNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE BRD4, BRD3, BRD2 RAB9A 3214/4885MEN1 2870/4885KMT2A 43/4885
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative BRD4, BRD3, BRD2 RAB9A 3214/4885MEN1 2870/4885KMT2A 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.